Navigation Links
Bioniche Pharma Acquires Baxter's ENLON(R) and ENLON-PLUS(R)
Date:7/2/2008

Three new products coming soon to Bioniche's growing line of injectable

products

LAKE FOREST, Ill., July 2 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the acquisition of Baxter Healthcare Corporation's ENLON product line, including:

-- ENLON(R) (edrophonium chloride injection, USP) 10 mg/mL, 15 mL vial

-- ENLON-PLUS(R) (edrophonium chloride, USP and atropine sulfate, USP)

Injection 5 mL ampule

-- ENLON-PLUS(R) (edrophonium chloride, USP and atropine sulfate, USP)

Injection, 15 mL Multi-dose Vial

Bioniche purchased the rights and certain assets related to the ENLON(R) product line from Baxter, which discontinued ENLON(R) in February 2008. Bioniche anticipates launching all three codes of ENLON(R) in October 2008.

"We are pleased to reintroduce these products, providing health care professionals with access to additional options," said Steve Thornton, CEO Bioniche Pharma.

According to IMS data, 2007 sales of ENLON(R) and ENLON-PLUS(R) totaled $2,727,000 and 307,000 units.

About ENLON(R) and ENLON-PLUS(R)

ENLON(R) is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. ENLON(R) is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.

ENLON-PLUS(R) (edrophonium chloride, USP and atropine sulfate, USP) Injection is recommended as a reversal agent or antagonist of nondepolarizing neuromuscular blocking agents. It is not effective against depolarizing neuromuscular blocking agents. It is also useful if used adjunctively in the treatment of respiratory depression caused by curare overdosage.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology and dermatology. The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois. More information about Bioniche Pharma can be found at http://www.bionichepharma.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)


'/>"/>
SOURCE Bioniche Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bioniche Reports Fiscal 2007 Year-End Results
2. Pharmacy Students Taught Improved Medication Adherence and Holistic Health Services Through Program Incorporating InforMedixs Med-eXpert(TM) System
3. Transcept Pharmaceuticals Appoints Key Senior Executives
4. Aureus Pharma Announces Date of 2008 Annual User Symposium
5. WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR
6. Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications
7. CET Life Sciences Center Welcomes Belmont University School of Pharmacy as New Tenant
8. Pharmasset Joins Russell 3000 Index
9. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
10. Webcast Alert: Isis Pharmaceuticals Announces a Business Update Conference Call
11. Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 23, 2017  In Atlanta, it seems everyone has a ... intertwine to create an expressive and dynamic community unlike any ... and contribute to it. With their newest ... seeks to carry on that tradition with a unique, ... salon is the newest of 13 nationwide locations, ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... (FDA) de novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® ... adults at home or in healthcare facilities during periods of rest. A lightweight, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Today, researchers can fast-track ... uric acid, and/or other biomarkers or SNPs of interest) using one, easy-to-collect saliva ... , the relationship between insulin and other relevant biomarkers can be extensively studied ...
(Date:2/23/2017)... Feb. 23, 2017 Aviva Systems Biology ... the acquisition of GenWay Biotech Incorporated, a protein ... and product offering for both the research and ... growth and enhance capabilities for both entities. GenWay,s 18 ... assays will nicely complement ASB,s objective to become ...
Breaking Biology Technology:
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a market ... new white paper " What You Should Know About ... of ensuring user authenticity is a growing concern. In ... of users. However, traditional authentication schemes such as username/password ... Biometric authentication offers an elegant solution to the ...
(Date:1/26/2017)... , Jan. 26, 2017  Crossmatch, a leading provider ... new solution aimed at combatting fraud, waste and abuse ... introduced at the Action on Disaster Relief conference in ... point for UN agencies and foreign assistance organizations throughout ... waste and abuse are a largely unacknowledged problem in ...
(Date:1/23/2017)... , Jan. 23, 2017  The latest mobile ... smartphone prices have dropped dramatically. The quarterly average price ... 2013 to $276 in Q4 2016.  There are now ... price of $116, up from just 28 a year ... According to Maxine Most , Acuity Market ...
Breaking Biology News(10 mins):